We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s drug pricing watchdog is recommending reimbursement of Bristol-Myers Squibb’s melanoma combination treatment of Opdivo and Yervoy, provided the company discounts the latter. Read More
The Justice Department was handed a surprise setback Friday when a jury acquitted Warner Chilcott’s former president of conspiring to pay kickbacks to physicians for prescribing seven of the company’s drugs. Read More
Despite appeals, the UK’s drug pricing watchdog has held firm against reimbursing Vertex Pharmaceuticals’ cystic fibrosis drug Orkambi, once again noting its modest short-term benefits to lung function and unknown long-term improvements. Read More
The UK’s National Institute for Health and Care Excellence refused to recommend Janssen’s chronic lymphocytic leukemia treatment Imbruvica for reimbursement in June, but left the door open to further discussion. Read More
While retail prices for cancer drugs may be the highest in the U.S., these medicines appear to be less affordable in poorer countries such as India and China despite their lower prices, according to a study. Read More
Colombia’s Ministry of Health and Social Protection announced its plans to unilaterally cut the price of Novartis’ myeloid leukemia treatment Gleevec after negotiations with the Swiss drugmaker fell through the cracks. Read More
Amgen is suing generics maker Sandoz, claiming that Sandoz’s attempts to market a biosimilar for the blockbuster bone marrow drug Neulasta infringes on two of its patents for the drug. Read More
The majority of physicians in the U.S. are familiar with biologics and biosimilars, but many lack the technical knowledge of their structural and therapeutic differences. Read More